Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Commercial services tags : Phase 3 save search
Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial
Published: 2021-12-29 (Crawled : 14:00) - biospace.com/
SLRX | $0.4848 -2.88% 6.2K
|
Commercial Services
|
| O: -2.86%
H: 5.69%
C: -3.43%
als ongoing trial phase 1 phase 2 milestone phase 3
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
Published: 2021-11-15 (Crawled : 13:30) - biospace.com/
CELC | $17.22 5.06% 4.82% 230K
|
Commercial Services
|
| O: -4.0%
H: 1.15%
C: 1.15%
collaboration phase 3 trial
S&P Global and IHS Markit Update on Pending Merger Following CMA's Phase 1 Findings
Published: 2021-10-19 (Crawled : 12:00) - prnewswire.com
SPGI | $412.56 -0.2% 0.0% 1.1M
|
Commercial Services
|
| O: 0.46%
H: 0.72%
C: 0.26%
phase 1 merge phase 3 phase 2
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: -28.7%
H: 39.15%
C: 36.75%
positive results phase 1 positive results trial obesity phase 2 phase 3
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
Published: 2021-09-27 (Crawled : 23:00) - globenewswire.com
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: -28.7%
H: 39.15%
C: 36.75%
phase 1 trial phase 2 phase 3
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: 2.19%
H: 34.76%
C: 13.99%
phase 1 positive trial phase 3 phase 2 obesity
Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients With Glioblastoma at Northwestern University
Published: 2021-03-11 (Crawled : 16:02) - biospace.com/
XCUR 4 | $0.5825 0.64% 0.64% 22K
|
Commercial Services
|
| O: 2.58%
H: 28.64%
C: 25.63%
results trial nu-0129 phase 3 phase 1 phase 2 glioblastoma
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
Published: 2021-02-25 (Crawled : 12:05) - globenewswire.com
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: -3.93%
H: 4.68%
C: -8.56%
covid adcovid phase 1 vaccine trial phase 3 phase 2 enroll
Altimmune Announces FDA Clearance of AdCOVID™ IND ApplicationEnrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week
Published: 2021-02-17 (Crawled : 15:00) - biospace.com/
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: 3.04%
H: 11.32%
C: 10.5%
covid fda clearance fda adcovid phase 1 vaccine trial phase 3 phase 2 clearance
Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients
Published: 2021-02-17 (Crawled : 13:00) - globenewswire.com
SLRX | $0.4848 -2.88% 6.2K
|
Commercial Services
|
| O: 9.43%
H: 3.45%
C: -6.9%
phase 1 expansion trial phase 3 phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.